Comments To FDA Suggest 510(k) Rescission Proposed Rule Needs Reworking
This article was originally published in The Gray Sheet
Executive Summary
FDA's proposed rule on 510(k) rescission does not provide an acceptable framework for appealing rescission and is untenable as it is currently written, industry comments recently submitted to FDA suggest.